1,568 trials (keyword fallback)
Cervical Abnormalities · Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Cancer
Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…
Cesarean Section
Primary: Induction to Delivery Interval — 268; 276 seconds
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Scapular Dyskinesis
Primary: Whole-muscle Activation — .046; .043; .040; .061 V
Fibromyalgia · Multiple Sclerosis · Osteoarthritis
Primary: Changes From Baseline in Physical Activity — 0.36; 0.31; 0.43; 0.76 units on a scale
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Cardiovascular Risk Factor
Primary: Change in Moderate (or Higher) Physical Activity Duration Following Message Receipt — 0.16; 0.13; 0.25; 0.31 minutes — p=0.037
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Body Dissatisfaction
Primary: Self-Ratings of Thought Appraisals (Believability) — 78.33; 77.97; 83.23; 74.74 score on a scale — p=<0.001
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: Prevalence of Anxiety Episodes (Crohn's Disease) — 262; 892 Participants
Seasonal Influenza · Vaccine
Primary: Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV — 1; 2; 204; 488 Subjects
Prostate Hypertrophy · Renal Disease
Primary: Surgical Rating Scale — 4; 4.7 units on a scale (1-5) — p=<0.001
COVID-19 Vaccines
Primary: Number of Participants Reporting Solicited Local Adverse Reactions (ARs) — 4060; 909; 467; 416 Participants
Polycystic Ovary Syndrome (PCOS) · Obstructive Sleep Apnea · Obesity
Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85
Arthropathy of Hip
Primary: Surgical Conditions — 1; 2; 11; 10 Participants